STAT reported that trial patients experienced a cure of fever and respiratory symptoms. Almost all patients were discharged in less than a week, he said.
The shares of remdesivir developer Gilead Sciences rose by more than 14% in out-of-hours transactions.
EXPERIMENTAL DRUG CORONAVIRUS REMDESIVIR MAKES EARLY PROMISE, SAYS RESEARCH
About 125 more people with COVID-19, 113 with severe symptoms, have been recruited through Chicago Medical University in the two Gilead Phase 3 clinical trials, according to STAT. The news received a recorded video discussion of the verification results.
In the video, Kathleen Mullane, an infectious disease specialist at the University of Chicago who oversees remedivir studies, said most of the patients had already been discharged from the hospital and two had died, according to STAT.
“Partial knowledge of an ongoing clinical trial is by definition incomplete and deserves never to be used to draw conclusions about the protection or effectiveness of a possible remedy under investigation,” a University of Chicago Medical Spokesperson said in a statement sent to Fox News. “In this case, data from an internal forum for fellow researchers related to the paintings in process were disseminated without authorization. Drawing conclusions at this level is inappropriate and scientifically incorrect.”
A Galaad spokeswoman told Fox News that all knowledge needed to be analyzed to draw conclusions from the trial. “Anecdotal reports, while encouraging, do not provide the statistical strength to determine the protection and efficacy profile of remedivir as a remedy for COVID-19,” he said in an email statement. “We hope that knowledge of our Phase 3 test in patients with severe COVID-19 infection will be available until the end of this month, and that more knowledge will be gained from other studies in May.”
“We are grateful for all the efforts of researchers and patients involved in our studies and look forward to sharing the effects of the full set of knowledge,” she added.
We perceive the urgent need for a COVID-19 remedy and the resulting interest in the knowledge of our remdesivir, an experimental antiviral drug. All knowledge must be analyzed to draw conclusions from the trial. Anecdotal, while encouraging, reports do not provide statistical strength to determine the protection and efficacy profile of remdesivir as a remedy for COVID-19. We hope that knowledge of our Phase 3 exam in patients with severe COVID-19 infection will be available until the end of this month, and that more knowledge will be available from other studies in May. We are grateful for all the efforts of the researchers and patients involved in our studies and look to the future to share the effects of the comprehensive knowledge set.
RE-DIVIDED: WHAT YOU NEED TO KNOW ABOUT THE POTENTIAL TREATMENT OF CORONAVIRUS
The report arrives less than a week after small studies found that remdesivir looks promising in the war against the coronavirus epidemic.
The study, which was published in the New England Journal of Medicine, was endorsed by Gilead Sciences.
Remdesivir is still awaiting regulatory approval as a remedy for coronavirus.
GILEAD OFFERS UPDATE ON EXPERIMENTAL TREATMENT OF CORONAVIRUS
Antiviral was used in the past to treat ebola patients and has attracted great attention as global struggles to involve the coronavirus pandemic. Experts, however, have warned that other people do not take medications unless prescribed by a doctor.
Repopulation is one of many that stand out as the U.S. tries to engage the pandemic. At a news convention last month, President Trump and the Food and Drug Administration (FDA) commissioner, Dr. Stephen Hahn, described several approaches being tested, such as chloroquine, a drug that is long used to treat and screened for malaria.
In an open letter published last week, Gilead CEO Daniel O’Day explained that seven clinical trials have been conducted to determine whether remdesivir is a safe and effective remedy for COVID-19. “China presented the first two studies in early February for patients with severe and moderate symptoms of the disease,” he wrote. “Since then, five more trials have been introduced around the world.”
A FAMILY PATIENT WITH 34-YEAR-OLD CORONAVIRUS UNDER LIFE SUPPORT ASKS FOR AN EXPERIMENTAL DRUG
“Two Phase 3 studies are being conducted through Gilead in the spaces with the highest prevalence of COVID-19 in the United States, Asia and Europe,” O’Day added. “One of these considerations is that of patients with a serious illness and other studies of remedivir in patients with more moderate symptoms.”
The U.S. National Institute of Allergy and Infectious Diseases (NIAID). And the World Health Organization (WHO) is also conducting trials, respectively.
“We hope to have an initial knowledge of re-ivir in serious patients until the end of April and will work temporarily to interpret and focus the results,” O’Day said in the letter. “The publication of knowledge of Chinese trials on remdesivir is the duty of Chinese researchers, however, we have been informed that patients with severe symptoms have been discontinued due to the blocking of recruitment. We look forward to review published knowledge when available. »
MORE THAN ONE Hundred YEARS BEFORE THE CORONAVIRUS, THE PANDEMIC OF SPANISH INFLUENZA ASOLA THE WORLD
In May, Gilead expects to discharge initial knowledge of the placebo-controlled NIAID trial, as well as his own from patients with moderate coVID-19 symptoms.
Last month, Gilead announced adjustments to his repair program. The company has implemented the “extended access” program to allow hospitals and physicians to request emergency use of remdesivir for several critically ill patients at once. The old “compassionate use” program is now aimed at young people and pregnant women.
In another open letter sent last month, O’Day said Gilead was accelerating reemployment production, a procedure that requires specialized chemistry and chain reactions.
CLICK HERE FOR FULL COVERAGE OF CORONAVIRUS
CLICK HERE TO SEE THE FOX NEWS APP
As of Thursday afternoon, more than 2.13 million cases of coronavirus worldwide had been diagnosed, adding at least 654301 in États-Unis.La disease caused at least 142735 deaths worldwide, adding up at least another 31590 people in the United States.
Chris Ciaccia of Fox News contributed to this article.
Follow James Rogers on Twitter @jamesjrogers